Press Release: PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results

Dow Jones
Nov 13

Lucid Diagnostics' EsoGuard(R) now fully reimbursed by Medicare nationwide

Veris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early 2027 FDA submission

PAVmed engaged with FDA on PortIO and Octeris

Conference call and webcast to be held today, November 13, at 8:30 AM EST

NEW YORK, Nov. 13, 2026 /PRNewswire/ -- PAVmed Inc. $(PAVM)$ ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid"), Veris Health Inc. ("Veris"), and Octeris Medical Inc. ("Octeris"), and reported financial results for the third quarter ended September 30, 2026.

Conference Call and Webcast

The webcast will take place on Friday, November 13, 2026, at 8:30 AM EST and is accessible in the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.

Business Update Highlights

"We're very encouraged by developments across the PAVmed portfolio," said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. "Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone. As Lucid's largest common shareholder, PAVmed stands to benefit directly from Lucid's substantial near-term revenue opportunity. Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission. We are also now actively engaged with FDA on both PortIO and Octeris. We believe this progress puts PAVmed in a strong position to create real long-term shareholder value."

Highlights from the third quarter and recent weeks:

   -- Lucid Diagnostics: 
 
          -- Began receiving payments from Medicare for the 
             EsoGuard(R) Esophageal DNA Test in October. Lucid is submitting 
             Medicare claims for tests performed at its Texas laboratory to 
             Novitas, the Medicare Administrative Contractor (MAC) with 
             jurisdiction over that laboratory, and is receiving payments at 
             EsoGuard's established Clinical Laboratory Fee Schedule rate. 
 
          -- Focused commercial efforts on expanding EsoGuard access among 
             at-risk Medicare beneficiaries, who represent approximately 50% of 
             the 30 million patients recommended for esophageal precancer 
             testing by professional society guidelines. 
 
          -- Announced publication of an 11,991-patient real-world EsoGuard 
             study in the peer-reviewed journal Diagnostics, the largest 
             peer-reviewed study of nonendoscopic esophageal precancer testing 
             to date, demonstrating the efficiency and scalability of the 
             EsoCheck(R) Esophageal Cell Collection Device. 
 
          -- Performed 2,871 EsoGuard tests and recognized revenue of $1.2 
             million in 3Q26. October was a record month for EsoGuard test 
             volume, with more than 1,800 tests. 
 
   -- Veris Health: 
 
          -- Monthly patient enrollment at OSU-The James grew throughout the 
             quarter, nearly doubling from July to September, as the commercial 
             phase of the strategic engagement continued to accelerate and the 
             clinical rollout went live across most departments. 
 
          -- Achieved design freeze for the implantable physiological monitor 
             and, in October, initiated the 90-day GLP animal study, keeping 
             the device on track for an early 2027 FDA 510(k) submission. 
 
   -- PortIO: 
 
          -- Held an initial meeting with FDA on PortIO in late October, to be 
             followed by an in-person pre-submission meeting in January 2027 
             focused on the device's regulatory pathway. 
 
   -- Octeris: 
 
          -- Completed Octeris' next-generation multimodal endoscopic imaging 
             probe, which is ready for clinical testing. Octeris expects to 
             submit its initial FDA pre-submission package this month, with 
             enrollment in the University of North Carolina clinical validation 
             study expected to begin in January 2027. 

Preliminary Financial Results:

   -- For the three months ended September 30, 2026, operating expenses were 
      approximately $6.8 million, which included stock-based compensation 
      expenses of $1.0 million. As shown below and for the purpose of 
      illustrating the effect of stock-based compensation and other non-cash 
      income and expenses on the Company's financial results, the Company's 
      non-GAAP adjusted net loss was approximately $1.2 million or $(0.19) per 
      common share. 
 
   -- PAVmed had cash and cash equivalents of $8.9 million, including 
      restricted cash of $5.3 million, as of September 30, 2026, compared to 
      cash and cash equivalents of $1.5 million, including $0.3 million of 
      restricted cash, as of December 31, 2025. 

PAVmed Non-GAAP Measures

   -- To supplement our financial results presented in accordance with U.S. 
      generally accepted accounting principles (GAAP), management provides 
      certain non-GAAP financial measures of the Company's financial results. 
      These non-GAAP financial measures include net loss before interest, taxes, 
      depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which 
      further adjusts EBITDA for stock-based compensation expense, loss on the 
      issuance or modification of convertible securities, the periodic change 
      in fair value of convertible securities, and loss on debt extinguishment. 
      The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted 
      loss are not recognized terms under U.S. GAAP. 
 
   -- Non-GAAP financial measures are presented with the intent of providing 
      greater transparency to the information used by us in our financial 
      performance analysis and operational decision-making. We believe these 
      non-GAAP financial measures provide meaningful information to assist 
      investors, shareholders, and other readers of our financial statements in 
      making comparisons to our historical financial results and analyzing the 
      underlying performance of our results of operations. These non-GAAP 
      financial measures are not intended to be, and should not be, a 
      substitute for, considered superior to, considered separately from, or as 
      an alternative to, the most directly comparable GAAP financial measures. 
 
   -- Non-GAAP financial measures are provided to enhance readers' overall 
      understanding of our current financial results and to provide further 
      information for comparative purposes. Management believes the non-GAAP 
      financial measures provide useful information to management and investors 
      by isolating certain expenses, gains, and losses that may not be 
      indicative of our core operating results and business outlook. 
      Specifically, the non-GAAP financial measures include non-GAAP adjusted 
      loss, and its presentation is intended to help the reader understand the 
      effect of the loss on the issuance or modification of convertible 
      securities, the periodic change in fair value of convertible securities, 
      the loss on debt extinguishment and the corresponding accounting for 
      non-cash charges on financial performance. In addition, management 
      believes non-GAAP financial measures enhance the comparability of results 
      against prior periods. 
 
   -- A reconciliation to the most directly comparable GAAP measure of all 
      non-GAAP financial measures included in this press release for the three 
      and nine months ended September 30, 2026 and 2025 are as follows: 
 
 
                        For the three months ended       For the nine months ended 
                               September 30,                    September 30, 
                           2026            2025             2026            2025 
                      --------------  ---------------  --------------  -------------- 
(in thousands 
except per-share 
amounts) 
Revenue               $           41  $             5  $           96  $           19 
Operating expenses             6,768            4,849          21,879          15,022 
Other (Income) 
 Expense, net                  6,308            1,167         (1,087)        (15,291) 
                      --------------  ---------------  --------------  -------------- 
Net (Income) Loss             13,035            6,011          20,696           (288) 
                      --------------  ---------------  --------------  -------------- 
 
Net income (loss) 
 attributable to 
 common 
 stockholders               (11,752)          (6,328)        (24,219)         (1,942) 
Preferred Stock 
 dividends and 
 deemed dividends                 97              945           7,120           3,606 
                      --------------  ---------------  --------------  -------------- 
 Net income (loss) 
  as reported               (11,655)          (5,383)        (17,099)           1,664 
Adjustments: 
 Depreciation and 
  amortization 
  expense(1)                      19               22              58              87 
 Interest expense, 
  net(2)                         (2)              (2)            (26)             (8) 
 NCI ownership share 
  of Interest and 
  Depreciation 
  adjustments                  (268)               --           (775)              -- 
                      --------------  ---------------  --------------  -------------- 
EBITDA                      (11,906)          (5,363)        (17,842)           1,743 
 
Other non-cash or 
financing related 
expenses: 
 Stock-based 
  compensation 
  expense(3)                     967              383           2,065           1,475 
 Operating expenses 
  issued in 
  stock(1)                       140               52           2,091             155 
 Change in FV equity 
  method 
  investments                  9,985            4,382          10,612         (5,979) 
 Preliminary Change 
  in FV convertible 
  debt(2)                      (330)              100         (3,126)             349 
 Loss on debt 
  extinguishment(2)               --               --           3,422              58 
 Change in fair 
 value -- warrant 
 liability                        --               --         (1,831)              -- 
 Change in fair 
  value -- rights 
  liability                     (96)               --           (150)              -- 
                      --------------  ---------------  --------------  -------------- 
Non-GAAP adjusted 
 (loss)                $     (1,240)   $        (446)   $     (4,759)   $     (2,199) 
                      ==============  ===============  ==============  ============== 
 Non-GAAP shares 
  outstanding, basic 
  and diluted                  6,640              718           4,849             596 
 Non-GAAP adjusted 
  (loss) income per 
  share, basic and 
  diluted             $       (0.19)   $       (0.62)  $       (0.98)  $       (3.69) 
 
 
(1) Included in general and administrative expenses in the financial 
statements. 
(2) Included in other income and expenses. 
(3) Stock-based compensation ("SBC") expense is included in operating expenses 
and is detailed as follows in the table below by category within operating 
expenses for the non- GAAP Net operating expenses: 
 
 
 
(in thousands 
except per-share     For the three months ended      For the nine months ended 
amounts)                    September 30,                   September 30, 
                        2026            2025            2026            2025 
                   --------------  --------------  --------------  -------------- 
 
Cost of revenue    $          158  $           55  $          377  $          133 
 Stock-based 
 compensation 
 expense(3)                    --              --              --              -- 
                   --------------  --------------  --------------  -------------- 
 Net cost of 
  revenue                     158              55             377             133 
                   ==============  ==============  ==============  ============== 
 
Sales and 
 marketing                    206             201             636             668 
 Stock-based 
  compensation 
  expense(3)                 (17)            (13)            (30)            (59) 
                   --------------  --------------  --------------  -------------- 
 Net sales and 
  marketing                   189             188             606             609 
                   ==============  ==============  ==============  ============== 
 
General and 
 administrative             4,482           3,505          15,489          11,557 
 Depreciation 
  expense                    (19)            (22)            (58)            (87) 
 Operating 
  expenses issued 
  in stock                  (140)            (52)         (2,091)           (155) 
 Stock-based 
  compensation 
  expense(3)                (899)           (332)         (1,927)         (1,276) 
                   --------------  --------------  --------------  -------------- 
 Net general and 
  administrative            3,424           3,099          11,413          10,039 
                   ==============  ==============  ==============  ============== 
 
Research and 
 development                1,922           1,088           5,377           2,664 
 Stock-based 
  compensation 
  expense(3)                 (51)            (38)           (108)           (140) 
                   --------------  --------------  --------------  -------------- 
 Net research and 
  development               1,871           1,050           5,269           2,524 
                   ==============  ==============  ==============  ============== 
 
Total operating 
 expenses                   6,768           4,849          21,879          15,022 
 Depreciation and 
  amortization 
  expense                    (19)            (22)            (58)            (87) 
 Operating 
  expenses issued 
  in stock                  (140)            (52)         (2,091)           (155) 
 Stock-based 
  compensation 
  expense(3)                (967)           (383)         (2,065)         (1,475) 
                   --------------  --------------  --------------  -------------- 
 Net operating 
  expenses          $       5,642   $       4,392   $      17,665   $      13,305 
                   ==============  ==============  ==============  ============== 
 

About PAVmed and its Subsidiaries

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard(R) Esophageal DNA Test and EsoCheck(R) Esophageal Cell Collection Device--the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.

For more information about PAVmed, please visit pavmed.com.

For more information about Lucid Diagnostics, please visit luciddx.com.

For more information about Veris Health, please visit verishealth.com.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's and Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's and Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's and Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's and Lucid's clinical and preclinical studies; whether and when PAVmed's and Lucid's products are cleared by regulatory authorities; market acceptance of PAVmed's and Lucid's products once cleared and commercialized; PAVmed's and Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's and Lucid's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's and Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-provides-business-update-and-reports-preliminary-third-quarter-2026-financial-results-302938900.html

SOURCE PAVmed Inc.

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10